| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cerus Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.14 |
| 52 Week High | US$6.95 |
| 52 Week Low | US$3.91 |
| Beta | 1.11 |
| 1 Month Change | 0% |
| 3 Month Change | -5.93% |
| 1 Year Change | -25.01% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 25.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| CU2 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | -1.7% |
| 1Y | -25.0% | 0.7% | 6.2% |
Return vs Industry: CU2 underperformed the German Medical Equipment industry which returned -2.7% over the past year.
Return vs Market: CU2 underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| CU2 volatility | |
|---|---|
| CU2 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: CU2 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CU2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 638 | Obi Greenman | www.cerus.com |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Cerus Corporation Fundamentals Summary
| CU2 fundamental statistics | |
|---|---|
| Market cap | €667.24m |
| Earnings (TTM) | -€38.28m |
| Revenue (TTM) | €157.91m |
4.2x
P/S Ratio-17.4x
P/E RatioIs CU2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CU2 income statement (TTM) | |
|---|---|
| Revenue | US$157.88m |
| Cost of Revenue | US$74.93m |
| Gross Profit | US$82.95m |
| Other Expenses | US$121.22m |
| Earnings | -US$38.27m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 52.54% |
| Net Profit Margin | -24.24% |
| Debt/Equity Ratio | 94.1% |
How did CU2 perform over the long term?
See historical performance and comparison